

## REMARKS

After amendment, the pending claims are 1, 32, 33, 35-37, 39, 44, and 46.

### **Specification and Sequence Listing Amendments**

The sequence listing of the specification was amended to incorporate sequences identified in the original specification and input in PatentIn 3.2 format. Specifically, SEQ ID NOS: 89-96 were incorporated into the original sequence listing. Support for the sequences of SEQ ID NOS: 89-96 is found in the original specification on page 5, lines 13-17; page 38, lines 5-18; page 38, line 38 through page 39, line 8; page 42, lines 23-32; page 50, lines 13-27; page 58, line 24 through page 59, line 1; and Figure 7. No new matter is added by this amended sequence listing.

Similarly, the specification was also amended to insert new sequence ID numbers for sequences in the specification that were the previously unidentified. The new sequence ID numbers, i.e., SEQ ID NOS: 89-96 are provided by the amended sequence listing. No new matter is added by these specification amendments.

Further, as required under 37 CFR § § 1.821 through 1.825, Applicant has submitted the following items.

- (i) Statement to Support Filing and Submission in accordance with 37 CFR § § 1.821 through 1.825;
- (ii) Substitute pages of the Amended Sequence Listing; and
- (iii) Substitute copy of the computer readable form of the amended Sequence Listing.

### **Claim Amendments**

Claim 46 was amended to refer to the nucleic acid sequence of SEQ ID NO: 96, which is provided in the amended Sequence Listing attached hereto.

For the Examiner's information, SEQ ID NO: 13 is the genomic sequence of KLK-L2. SEQ ID NO: 96 is the cDNA, the spliced together exons of SEQ ID NO: 13 when the introns are removed, as illustrated in Figure 7. The nucleic acid sequence of SEQ ID NO: 96 therefore encodes the KLK-L2 amino acid sequence of SEQ ID NO: 14.

The nucleic acid sequence of SEQ ID NO: 96 thus finds support in Figure 7, which figure provides the complete sequences for SEQ ID NOS: 14 and 96. No new matter is added by this claim amendment.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicant

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
(215) 540-9200